ARE YOU ADAPTIVE? We’re driving groundbreaking research in cancer and other immune-mediated diseases that translates into novel clinical diagnostics and innovative therapeutics. We are at the forefront of immune-based discoveries, transforming the future state of health through our disruptive, proprietary immunosequencing technology. With strong financial footing and rapid growth, we are looking for the brightest, most passionate and collaborative innovators to join us.
At Adaptive, you'll be challenged, you'll be inspired, and you'll be proud to be part of an innovative organization making a real impact on improving the quality of life globally. No matter what your role is, you'll find a diverse, team-driven, fun culture where your contributions truly count. #BeingAdaptive
About the clonoSEQ Assay
When it comes to treating cancers, a physician’s ability to detect minute traces of disease is critical to patient care. The clonoSEQ Assay is up to 100 times more sensitive than other leading minimal residual disease (MRD) detection methods. clonoSEQ MRD results allow a physician to adjust treatment based on disease burden, assess response to therapy over time, and monitor patients while in remission. Based on a physician’s judgment, these results may mean the possibility of earlier intervention or less unnecessary treatment.
NOTE: This role will have accountability for the Western US Region and may be located in any major metropolitan area within the West such as: Seattle, Portland, San Francisco, Los Angeles, San Diego, Denver, Phoenix.
The National Payer Accounts Director is pivotal to establishing clonoSEQ as the gold standard in MRD detection. This role is responsible for setting and executing coverage and contracting strategies for a targeted mix of National and Regional Payers (Regional Blues, Regional Independents, IDNs) to advance patient access for clonoSEQ in the US. This is a highly visible position within Adaptive responsible for identifying, developing and managing strategic relationships with payers and organizations that influence payer decision-making.
The successful candidate will have a proven track record of working with commercial payers in the US to secure favorable medical policy and adoption of innovative diagnostics, medical devices or therapies. The incumbent will drive execution of reimbursement strategies through a balance of business acumen, interpersonal skills and clinical aptitude (understanding of oncology disease/disorders, treatment pathways, and the role of personalized medicine approaches in patient care).